Breast cancer
Description
An in-depth report on the causes, diagnosis, treatment, and prevention of breast cancer.
Alternative Names
Mammograms; Mastectomy
References
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
N Engl J Med
. 2006 Jul 13;355(2):125-37.
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA
. 2006 Apr 12;295(14):1658-67.
Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Lancet Oncol
. 2006 Aug;7(8):633-43.
Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, et al. Unopposed estrogen therapy and the risk of invasive breast cancer.
Arch Intern Med
. 2006 May 8;166(9):1027-32.
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
J Clin Oncol
. 2005 Oct 20;23(30):7491-6.
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer.
JAMA
. 2006 Jul 12;296(2):193-201.
Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE). Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
J Clin Oncol
. 2006 Jul 20;24(21):3361-6.
Feigelson HS, Patel AV, Teras LR, Gansler T, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women.
Cancer
. 2006 Jul 1;107(1):12-21.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
J Natl Cancer Inst
. 2005 Nov 16;97(22):1652-62.
Gradishar WJ, Cella D. Selective estrogen receptor modulators and prevention of invasive breast cancer.
JAMA
. 2006 Jun 21;295(23):2784-6.
Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience.
J Clin Oncol
. 2006 Sep 1;24(25):4107-15.
Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, Solin LJ. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
J Clin Oncol
. 2006 Sep 1;24(25):4100-6.
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis.
JAMA
. 2005 May 25;293(20):2479-86.
Hortobagyi GN. Trastuzumab in the treatment of breast cancer.
N Engl J Med
. 2005 Oct 20;353(16):1734-6.
Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA
. 2006 Jun 21;295(23):2742-51.
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.
J Clin Oncol
. 2006 Jun 20;24(18):2917-31.
Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently iagnosed breast cancer.
N Engl J Med
. 2007 Mar 29;356(13):1295-303. Epub 2007 Mar 28.
Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
J Clin Oncol
. 2005 Oct 20;23(30):7703-20.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
J Natl Cancer Inst
. 2006 May 3;98(9):599-609.
Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Ann Intern Med
. 2005 Sep 6;143(5):362-79.
Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study.
Cancer
. 2006 May 1;106(9):2076-83.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med
. 2005 Oct 20;353(16):1659-72.
Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's HealthInitiative Randomized Controlled Dietary Modification Trial.
JAMA
. 2006 Feb 8;295(6):629-42.
Qaseem A, Snow V, Sherif K, et al. Screening mammography for women 40 to 49 years of age: A clinical practice guideline from the American College of Physicians.
Ann Intern Med
. 2007;146(7):511-515.
Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis.
J Clin Oncol
. 2006 Jun 20;24(18):2743-9.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
J Clin Oncol
. 2005 Nov 1;23(31):7804-10.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
N Engl J Med
. 2005 Oct 20;353(16):1673-84.
Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. A prospective study of female hormone use and breast cancer among black women.
Arch Intern Med
. 2006 Apr 10;166(7):760-5.
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography.
CA Cancer J Clin
. 2007;57(2):75-89.
Smith RA, Salsow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: Update 2003.
CA Cancer J Clin
. 2003;53(3):141-169.
Stefanick ML. Risk-benefit profiles of raloxifene for women.
N Engl J Med
. 2006 Jul 13;355(2):190-2.
Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
JAMA
. 2006 Apr 12;295(14):1647-57.
Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
Arch Intern Med
. 2006 Jul 24;166(14):1483-9.
Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
N Engl J Med
. 2005 Dec 29;353(26):2747-57.
U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
Ann Intern Med
. 2005 Sep 6;143(5):355-61.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA
. 2006 Jun 21;295(23):2727-41.
-
Review Date: 4/3/2007
-
Reviewed By: Editorial Team: Greg Juhn, M.T.P.W., David R. Eltz, Kelli A. Stacy. Previously reviewed by Harvey Simon, M.D., Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital (10/2/2006).
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's
accreditation program
is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s
editorial process
. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
|
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
